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Hepatotoxin responses <p>Histopathology, clinical chemistry, hematology and gene expression data were collected from the rat liver and blood after treatment  with eight known hepatotoxins.</p>
Abstract
This report details the standardized experimental design and the different data streams that were
collected (histopathology, clinical chemistry, hematology and gene expression from the target
tissue (liver) and a bio-available tissue (blood)) after treatment with eight known hepatotoxicants
(at multiple time points and doses with multiple biological replicates). The results of the study
demonstrate the classification of histopathological differences, likely reflecting differences in
mechanisms of cell-specific toxicity, using either liver tissue or blood transcriptomic data.
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Background
The use of genomic approaches to better understand the
adverse effects of environmental and xenobiotic exposures on
human injury and disease processes engendered a great deal
of early enthusiasm and excitement. This research initially
focused on using gene expression alterations as measured by
microarray analyses and is often referred to as 'toxicogenom-
ics' [1]. Quite early on, investigators were able to demonstrate
that exposure to different toxicants could be discriminated or
classified in rodent model systems by microarray profiling of
gene expression alterations in the target tissues, that is, tis-
sues that display visible adverse effects in response to toxi-
cant exposure [2-5].
Gene expression microarrays have developed over the past
decade into a powerful tool for investigating biological, mech-
anistic, and disease processes in addition to developing
genomic classifiers. Recent standardization efforts by the
Microarray Quality Control Consortium, the Toxicogenomics
Resource Consortium as well as other groups have clearly
demonstrated the reproducibility of transcript level data gen-
erated using these approaches [6-9]. However, in most
instances these studies have understandably been based on
reference samples with little or no biological significance. The
Microarray Quality Control Consortium did substantiate
their findings by performing a cross-platform study using
samples from a multi-agent rat toxicogenomics study at a sin-
gle dose and time point and the Toxicogenomics Resource
Consortium did perform a cross-laboratory, time course
assessment using samples from a single toxic agent [10,11].
However, there are still open questions regarding the utility
and applicability of the microarray technology in biological
research and in particular with respect to understanding and
classifying injury processes that arise as a consequence of
exposures to various agents. For example, can gene expres-
sion data distinguish similar biological responses that occur
in different physiological regions within an organ (for exam-
ple, necrosis within different zones of the liver lobule) or sim-
ilar lesions that are the result of exposure to different
compounds?
Linking gene expression changes with more traditional toxi-
cological measurements of adverse biological responses to
toxicants (for example, histopathology and clinical chemis-
try), referred to as 'phenotypic anchoring', allowed investiga-
tors to gain new insight into the processes involved in the
adverse effects on target tissues [12-15]. In addition to analy-
sis of target tissues, the use of whole blood as a tissue source
for gene expression profiling is extremely appealing and
already has been demonstrated for a variety of diseases and
exposures [16-22]. This has tremendous potential in a thera-
peutic setting - the use of blood as a surrogate for the primary
tissue of interest greatly facilitates sample collection and
analysis. The benefits would be realized in basic research
studies as well. If transcript data in whole blood can function
as a surrogate for the target organ, a researcher would be able
to collect serial time points from an animal as opposed to har-
vesting tissue at a single time point after sacrifice. This would
not only decrease the number of animals being used in a
study, but would increase the amount and value of the data
generated from a single animal as early transcriptional events
could be phenotypically anchored to histopathological obser-
vations or clinical chemistry data that were not observed until
later time points within the same animal. The amount of total
RNA required to perform microarray-based gene expression
profiling from whole blood continues to decrease, thereby
increasing the potential for practical applications. Thus, one
question of interest is whether expression data from whole
blood can serve as a surrogate for a target organ through
either an ability to detect the same transcript changes or an
ability to identify different transcript biomarkers with similar
or enhanced classification utility.
While much progress has been made in the application of tox-
icogenomics to the classification of toxicants and the investi-
gation of mechanisms of toxicity, a full realization of its
potential in a systems biology context, sometimes referred to
as 'systems toxicology' [23], has yet to be accomplished. A pri-
mary obstacle has been the lack of truly robust data sets that
capture not only genome-wide gene expression measure-
ments but also traditional biological and toxicological infor-
mation associated with exposures that vary over dose and
time. This need was recently highlighted in the National
Research Council's report on toxicogenomics [24]. Here we
present a comprehensive, public dataset of gene expression
and accompanying data (histopathology, clinical chemistry,
hematology) from a standardized study to serve as a resource
to further advance the development of systems toxicology.
The present report details the experimental design and the
different data that were collected, and provides examples of
how these data can be used to address important biological
questions. This investigation of eight known hepatotoxicants
was designed to evoke acute liver injury with similarities as
well as differences in the type and location of injury that
result.
The eight compounds are all acute hepatotoxins that cause
hepatocellular necrosis following a single administration at a
suitable dose. Most of the compounds target hepatocytes;
however, monocrotaline targets endothelial cells leading to
hemorrhage and activation of the coagulation system. The
toxicity of bromobenzene, 1,2- and 1,4-dichlorobenzene, N-
nitrosomorpholine, monocrotaline, and thioacetamide
require metabolic activation by various cytochrome P450s to
reactive intermediates [25-29]. Since cytochrome P450
expression occurs primarily in the perivenous to centrilobular
region of the hepatic plate, these agents generally damage the
centrilobular region of the liver. The toxicity of diquat is asso-
ciated with a one electron reduction/oxidation reaction that is
catalyzed by NADPH cytochrome c reductase and leads to the
production of high levels of reactive oxygen species [30]. The
mechanism responsible for the toxicity of galactosamine ishttp://genomebiology.com/2008/9/6/R100 Genome Biology 2008,     Volume 9, Issue 6, Article R100       Lobenhofer et al. R100.3
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not as well understood but is thought to be associated with
depletion of UTP caused by the conversion of galactosamine
to UDP-hexosamines and UDP-N-acetylhexosamines [31].
The work was performed in its entirety using standardized
procedures for the in-life work and for the generation of gene
expression microarray data (n = 1,704 hybridizations). Doses
that ranged from 'sub-toxic' to 'toxic' exposures were selected.
Additionally, gene expression profiling was performed on two
commercially available platforms (Agilent and Affymetrix)
for one of the tissues (liver), thereby providing an opportunity
to corroborate findings across platforms. In-life observations
were recorded and clinical chemistry, hematology, and liver
histopathology were also assessed for all 426 animals. These
additional data facilitate the phenotypic anchoring of the
gene expression data and confirm that the goal of the study to
evoke different types of liver injury was achieved. Gene
expression levels in whole blood were also assayed to evaluate
whether biomarkers of different types of liver damage could
be identified in this readily accessible bio-fluid.
The analyses presented here further demonstrate the utility of
using microarrays as a tool for gene expression profiling to
address biological questions. Specifically, this experiment
was designed to provide a means to generate mechanistic and
predictive measures of toxicity by integrating multiple data
streams that were recorded within this standardized study.
These model chemical exposure studies also provide a com-
prehensive data set with a well defined phenotypic anchor
(liver injury) that is needed to assess the utility of gene
expression profiling from whole blood samples. These data
can now serve as a rich resource to the scientific community
to test and validate these as well as other hypotheses, and
have been made freely available in a public repository [32-
34]. While the experimental design is based on a common
model for toxicogenomics studies, the findings and/or the
results of mining these data can be applied to other fields
using microarrays as a research tool.
Results and discussion
Experimental design
The motivation for this study was the need for a rich, public
dataset consisting of multiple types of data (gene expression,
histopathology, and so on) that could be interrogated to test
hypotheses regarding the application of gene expression pro-
filing data generated from microarrays. We therefore
designed a study with multiple compounds (n = 8) that would
induce a common phenotype (liver injury), while also differ-
ing in the extent and/or severity of the injury and/or the co-
occurrence of other noted histopathological observations,
such as the type of inflammatory cell infiltrates, the presence
of bile duct hyperplasia, and so on (Table 1). The selected
compounds are acute hepatotoxicants, requiring only a single
administration at a suitable dose to elicit a toxic response. All
eight compounds are rapidly absorbed from the gastrointesti-
nal tract following administration, but are not direct acting in
that they require biotransformation to toxic-reactive interme-
diates within the liver. From a preliminary dose finding study,
three doses were selected corresponding to a 'sub-toxic',
'moderately toxic' and 'toxic' dose for each compound (Table
2). Separate groups of four to six animals were treated with
compound at each of these doses or with a vehicle control at
time 0, and then sacrificed either 6, 24, or 48 hours later.
Blood and liver were harvested at the time of sacrifice for clin-
ical chemistry, hematology, histopathology and gene expres-
sion profiling using standardized procedures across all
compounds. Additional data file 1 details all of the measure-
ments that were collected, except the gene expression profil-
ing data, for all of the animals in this study. All data, including
the gene expression data, are available through a publicly
accessible website [34].
The expected result of exposure to both the moderately toxic
and toxic doses of these compounds (except for 1,4-dichlo-
robenzene) was necrosis within the liver lobule. For most
compounds it was expected that the necrosis would be local-
ized to the centrilobular region, whereas with diquat the dam-
age was expected to extend into the midzonal region, and with
galactosamine it was expected to be randomly distributed
throughout the liver. The histopathology data confirmed
these expectations; however, some individual animal varia-
bility was observed (Table 1 and Additional data file 1). Vari-
ability in the evoked phenotypic response is commonly
observed in these types of in-life studies, despite conducting
the experiments in an in-bred population using highly stand-
ardized procedures. Although such variability can be
confounding when the data are analyzed using dose, time,
and compound to organize groups, here we consider this var-
iability to be an asset in that it provided an opportunity to
examine molecular responses and mechanisms not only
according to the mode of action of the included compounds,
but also according to the severity and character of the
response irrespective of inducing compound. Furthermore,
this variability in response provides an opportunity to iden-
tify biomarkers that correlate with hyper- and hyposensitivity
in individual animals.
Compound-specific responses
Previous work has demonstrated that toxicants can be classi-
fied using gene expression data derived from the primary tar-
get tissue [2,3,35,36]. The compounds in this study were
chosen based on their ability to induce acute hepatotoxicity
and the similarities and differences in the type and location of
the damage resulting from exposure. Since the compounds in
this study are acute hepatotoxicants resulting in hepatocyte
necrosis, we wanted to corroborate these findings with chem-
icals that could be considered closely related based on the
damage they evoke.
For each compound there are three doses and three time
points for a total of nine dose/time groups with four to six ani-Genome Biology 2008, 9:R100
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mals in each group (the additional dose for diquat was omit-
ted from these analyses). A support vector machine (SVM)
approach was used to identify compound-specific classifiers
within each dose/time group for each tissue type (blood and
liver). The resulting classifiers (Additional data file 2) were
then used to group samples based on principal component
analyses and hierarchical clustering to determine whether or
not the classifiers functioned well at separating all of the ani-
mals within a dose/time group into different compound
groups.
An SVM identified 160 transcripts for the classification of the
8 compounds within the liver profile data of animals treated
with the medium ('toxic') dose and sacrificed at the 6 hour
time point. When the expression level data for these tran-
scripts were used to cluster the medium dose samples at the 6
hour time point, the classifiers separated the animals into the
eight different compound groups, with the exception of three
individual animals (two diquat animals (animals 2 and 6) and
one 1,2-dichlorobenzene animal (animal 2); Figure 1). Inter-
estingly, these animals had a noticeably different phenotypic
response compared to the other individuals in their com-
pound group or represent a compound group demonstrating
significant diversity in the manifested phenotype. For exam-
ple, three of the animals in the 1,2-dichlorobenzene group
(animals 1, 3, and 4) had minimal levels of hepatocellular
necrosis at this dose and time; however, the sample that did
not cluster (animal 2) with these animals did not have any
observable necrosis. The diquat treatment at this dose and
time point resulted in variability in regards to the phenotypic
response at the level of histopathology. Three of the six diquat
treated animals had no apparent histopathological observa-
tions, two had noted levels of glycogen depletion and one ani-
mal did have minimal levels of hepatocellular necrosis. While
the grouping of the samples in the cluster does not perfectly
reflect the three different levels of liver damage noted in this
compound group, the lack of grouping is consistent with the
variability in regards to the treatment response. This con-
firms that while transcript data from the primary target organ
can effectively classify compounds, this is true only inasmuch
as the treatment evokes a level of consistency in the response.
In instances in which the response to a particular dose of a
given compound is variable in regards to the phenotype that
is evoked, the transcript expression levels are more reflective
of the phenotype as opposed to the inducing compound.
These findings underscore the importance of phenotypical
anchoring.
When one considers the variability of the presence and sever-
ity of necrosis and the infiltration of inflammatory cells, it is
not surprising that gene expression data from a target organ
would not accurately group all of the samples within a given
compound. For this reason, the gene expression data gener-
ated from whole blood were examined to determine if these
data could more accurately group samples based on com-
pound. Blood is a highly accessible bio-fluid, yet is not the pri-
mary target tissue for compound toxicity. When the liver data
were examined, the SVM-identified classifiers for each of the
nine dose/time groups were not able to accurately group all of
the individuals into the eight compound groups. In contrast,
the classifiers that were generated using the blood data were
able to accurately group all of the individuals according to the
eight compounds in only one of the nine dose/time groups,
but performed better than the liver data at grouping individ-
u a l s  i n t o  c o m p o u n d  g r o u p s  i n  s i x  o f  t h e  n i n e  d o s e / t i m e
groups. Table 3 indicates the number of classifiers that were
identified for each dose/time group for each tissue type (as
well as the number of classifiers overlapping across the tissue
types within a dose/time group) and indicates the accuracy
each set of classifiers achieved in grouping all of the animals
into compound groups. Interestingly, the SVM classifiers
generated from blood data outperformed the SVM classifiers
Table 1
Hepatotoxicants studied
Compound Low dose 'sub-
toxic' (mg/kg)
Medium dose 
'moderately toxic' 
(mg/kg)
Medium high 
dose (mg/kg)
High dose 'toxic' 
(mg/kg)
Vehicle Delivery 
method
Primary site of 
livery injury
Bromobenzene 25 75 NA 250 Corn oil Oral gavage Centrilobular
1,2-Dichlorobenzene 15 150 NA 1,500 Corn oil Oral gavage Centrilobular
1,4-Dichlorobenzene 15 150 NA 1,500 Corn oil Oral gavage NA*
N-nitrosomorpholine 10 50 NA 300 PBS Oral gavage Centrilobular
Diquat 5 10 20 25 PBS Intraperitoneal 
injection
Mid-zonal to 
centrilobular
Monocrotaline 10 50 NA 300 PBS Oral gavage Centrilobular
Thioacetamide 15 50 NA 150 PBS Oral gavage Centrilobular
Galactosamine 25 100 NA 400 PBS Intra-peritoneal 
injection
Random
*1, 4-Dichlorobenzene was intended to function as a non-toxic analog of 1,2-dichlorobenezene; however, centrilobular hepatocyte necrosis was 
observed in one of the six low dose animals at 6 hours and all four of the high dose animals at the 24 hour time point. NA, not applicable; PBS, 
phosphate-buffered saline.http://genomebiology.com/2008/9/6/R100 Genome Biology 2008,     Volume 9, Issue 6, Article R100       Lobenhofer et al. R100.5
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generated from liver data in six of the nine dose/time groups;
the exceptions were the low dose, 6 hour group and the low
and high dose groups for the 48 hour time point. Though the
number of common classifiers across the tissue types within a
given dose/time group were small, this was not an unex-
pected finding considering that the target tissue is the site of
the injury whereas the blood represents a readily available tis-
sue source functioning as a surrogate (Table 3). Cumulatively,
these findings reinforce the utility of performing gene expres-
sion profiling experiments on blood as a suitable surrogate for
the target organ.
T r a n s c r i p t  d a t a  f r o m  b l o o d ,  h o w e v e r ,  w e r e  a l s o  u n a b l e  t o
group individual animals in some instances in which the com-
pound manifested different phenotypic responses across the
animals of that particular dose/time group. At the high dose/
48 hour time point, three of the compounds (diquat, thioa-
cetamide, and galactosamine) demonstrated variability in
regards to the extent of hepatocellular necrosis, the amount of
inflammatory cell infiltrates and/or indications of hepatocel-
lular repair (mitosis). Consistent with this observation, these
are also the three compounds that did not separate perfectly
in the dendrogram resulting from the hierarchical clustering
of the blood gene expression data for the 60 SVM-identified
classifiers for this dose/time group (Figure 2), suggesting that
the phenotypic response resulting from exposure to a given
compound was having a greater impact on the gene expres-
sion profile compared to a unified transcriptional response
resulting merely from the exposure to the compound per se.
Taken together, these results indicate that the details of the
injury resulting from compound application are a more
appropriate grouping than are the doses and time points of
individual compounds when using gene expression data from
the primary site of injury - in this case the liver - or when
using gene expression data from a surrogate source such as
whole blood.
Another illuminating trend in both liver and blood gene
expression data was the grouping of galactosamine and thio-
acetamide samples. For example, using the 160 SVM-identi-
fied classifiers generated from the blood data for the low
dose/6 hour samples, most of the samples within a given
compound group clustered together (Figure 3). It was not sur-
prising to observe several cases in which a specific animal did
not group with the others from a compound group since vir-
tually no histopathological phenotypes were observed at this
time point after exposure to a low dose. In fact, in most
instances this exposure dose did not elicit any injury at any of
the time points. However, the galactosamine and thioaceta-
mide samples grouped together. Interestingly, these are the
only two compounds that evoked biliary hyperplasia in this
study, albeit at a later time point (48 hours). Their grouping
in the low dose/6 hour samples suggests that they activate
similar transcriptional responses long before a common
Table 2
Summary of histopathological diagnoses and severities
Severity
Histopathological diagnosis None Minimal Mild Moderate Marked
Centrilobular hepatocyte necrosis 304 65 15 8 26
Centrilobular, mid-zonal hepatocyte necrosis 399 8 5 4 2
Mid-zonal hepatocyte necrosis 417 1 0 0 0
Focal hepatocyte necrosis 392 11 12 2 1
Centrilobular cellular infiltrates 333 50 17 13 5
Centrilobular, mid-zonal cellular infiltrates 400 5 8 5 0
Portal cellular infiltrates 394 16 5 3 0
Focal cellular infiltrates 370 34 10 4 0
Depletion glycogen 324 19 33 16 26
Centrilobular hepatocyte degeneration 403 9 3 3 0
Centrilobular, mid-zonal hepatocyte degeneration 402 4 7 5 0
Hepatocyte apoptosis 410 7 1 0 0
Hepatocyte hypertrophy 382 10 16 0 10
Hepatocyte fatty change 416 2 0 0 0
Bile duct hyperplasia 405 11 2 0 0
Congestion 397 10 5 6 0
Hemorrhage 384 34 0 0 0
Hepatocyte regeneration 412 3 0 2 1
Mitosis 393 12 5 4 4Genome Biology 2008, 9:R100
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visible phenotype is observed, despite the fact that these com-
pounds are not structurally related.
In order to assess the biological themes within each set of
classifiers, a Gene Ontology (GO) enrichment analysis was
performed on the classifiers for each tissue/time point/dose
group using GoMiner [37,38]. The enrichment p-values for all
GO categories that had at least five members measured by the
microarray are detailed in Additional data file 3. The GO cat-
egories that were found to be enriched in multiple tissue/time
point/dose groups revealed some interesting aspects of the
biology underlying the molecular response to the exposure to
these acute hepatotoxicants. Not surprisingly, categories like
'response to chemical stimulus' and 'response to wounding'
were found to be enriched in many of these groups. 'Taxis' and
'chemotaxis' were the most prevalently enriched GO catego-
ries in both tissue types, which likely reflects the differential
response with regards to the inflammatory cell infiltrates
across the compounds. 'Wound healing' was significantly
enriched in many of the time point/dose groups in the liver,
except at the time points associated with the high dose expo-
sure, which is consistent with the histopathological observa-
tions with the sub-toxic and moderately toxic doses.
Interestingly, this category was enriched at the 24 and 48
hour time points for the high dose exposures in blood. Also
surprising was the observation that classifiers annotated to
'wound healing' were different for each of these time points in
blood, potentially suggesting that the differences in the iden-
tity of the genes may represent some of the temporal
responses to the healing and repair processes that occurred
between the 24 and 48 hour time points.
Cumulatively, these results support the previous findings that
toxicants can be classified and differentiated based on gene
expression profiling data from the target organ [2,3,35,36],
but extends our understanding by determining that such
Hierarchical clustering of animals in the medium dose/6 hour group using SVM-derived classifiers Figure 1
Hierarchical clustering of animals in the medium dose/6 hour group using SVM-derived classifiers. Two-way hierarchical clustering using Ward's minimum 
variance as the heuristic criteria and Euclidean distance as the similarity metric was performed on all of the animals in the medium dose/6 hour group using 
the liver expression values for the 160 transcripts identified as compound classifiers for this dose/time group by a SVM algorithm. The degree of 
relatedness between each sample is represented by the dendrogram (hierarchical tree) presented in this figure, wherein the height of each branch 
represents the distance between the two objects being connected.http://genomebiology.com/2008/9/6/R100 Genome Biology 2008,     Volume 9, Issue 6, Article R100       Lobenhofer et al. R100.7
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results can also be obtained using whole blood. Importantly,
in instances where a specific dose of a compound resulted in
variable severity of liver injury, it was found that the specifics
of the injury were a more significant determinant of expres-
sion levels than were compound-specific patterns of expres-
sion. This strongly reinforces the need to phenotypically
anchor gene expression data in order to appropriately inter-
pret the results.
Transcript profiles of toxicity in whole blood
Having demonstrated the utility of performing gene expres-
sion profiling on whole blood samples as an effective surro-
gate for the target organ to classify compound exposures, we
sought to further explore the utility of this readily available
sample source by establishing whether blood transcript data
could provide insights into the presence and severity of injury
within a target organ upon toxicant exposure. In previously
published work using these same in-life studies, we detailed
an approach to compile histopathological diagnoses into
common biological themes and to appropriately weigh and
score these observations [39]. Using this approach, the diag-
noses involving 'glycogen depletion', 'hypertrophy', 'fatty
change', and 'necrosis' were combined in a 'Response to hepa-
tocellular injury' category. For each individual animal in this
study, a score was calculated for this category based on the
absence or presence (and associated severity score) of the his-
topathological observation comprising this category (Addi-
tional data file 1). These scores were used as the factor level in
a one-way analysis of variance (ANOVA) involving the gene
expression data from whole blood. A total of 30 transcripts
was found to vary significantly (p-value ≤ 1 × 10-7) across the
factor levels. Interestingly, over 60% of these transcripts (n =
19) overlap with the set of 3,659 transcripts that were
identified using the same ANOVA approach with the liver
gene expression data [39]. The gene expression data from all
318 rats for this group of 30 transcripts were then used in a
principal component analysis (PCA). The resulting visualiza-
tion from this analysis (Figure 4) reveals that the variability
contained in the first principal component (the combination
of variables that explains the greatest amount of variation)
provides good separation of the individuals based on their
'Response to hepatocellular injury' score as indicated by the
increasing trend from left to right in the figure. The
separation is not perfect, which is expected when one consid-
ers that this is only a portion of the biological response to
treatment that these animals undergo. However, this clearly
illustrates the power to be able to detect not only the presence
of liver injury, but also an indication of severity using tran-
script data from whole blood.
Conclusion
We have generated a data set that will be a unique and valua-
ble resource for the environmental health and toxicological
research community. The results of the study presented here
demonstrate that, using this data set, differences in the phe-
notypic manifestation of diverse hepatotoxicants can be
resolved by microarray analysis. It was possible to classify
histopathological differences, most likely reflecting differ-
ences in mechanisms of cell-specific toxicity, using either
liver tissue or blood. Such data may allow for mechanistic
inference and lead to a more precise definition of the poten-
tial hepatotoxicity of new compounds. In addition, the avail-
ability of public access to the data derived from these studies
provides a resource to other investigators pursuing these and
related issues.
Table 3
SVM classifier accuracy
Blood Liver
Time (Hours) Dose Number of 
animals in 
the dose/
time groups
Animals 
correctly 
grouped by 
compound
Percentage 
grouped 
correctly
Number of 
classifiers
Animals 
correctly 
grouped by 
compound
Percentage 
grouped 
correctly
Number of 
classifiers
Overlap of 
classifiers
6 Low 34 27 79.4 160 32 94.1 110 12
6 Medium 34 32 94.1 210 31 91.2 160 17
6 H i g h 3 4 3 08 8 . 21 0 2 36 7 . 61 0 0
24 Low 34 33 97.1 110 28 82.4 310 16
24 Medium 34 34 100.0 360 30 88.2 60 12
24 High 34 32 94.1 360 30 88.2 10 0
48 Low 34 30 88.2 210 32 94.1 360 22
48 Medium 34 33 97.1 310 32 94.1 460 36
48 High 28 22 78.6 60 27 96.4 10 1
Average 90.8 Average 88.5Genome Biology 2008, 9:R100
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Materials and methods
Animals and animal care
Male Fischer 344/N rats approximately 10-12 weeks old were
obtained from Taconic laboratory animals (Germantown, NY,
USA). The animals were acclimated for 14 days and observed
for absence of disease. All studies were conducted at Inte-
grated Laboratory Systems, Inc. (Research Triangle Park, NC,
USA). The rats were kept two per polycarbonate cage (Lab
Products, Inc., Maywood, NJ, USA) with Sani-Chips bedding
(PJ Murphy Forest Products Corp., Montville, NJ, USA). The
animal rooms were maintained at 17-25°C and 33-96%
relative humidity with a 12 hour dark-light cycle and 10 room
air changes per hour. Cages were changed twice per week and
NTP-2000 diet and tap water were provided ad libitum.
In-life studies
Hepatotoxicants were identified based on published litera-
ture and chosen due to their ability to injure different cell
types and regions of the liver. Doses were determined with
pilot experiments. For each chemical, doses that elicited a
sub-toxic ('low'), a moderately toxic ('medium') or a overtly
toxic ('high') response 24 hours after treatment were selected.
The doses, vehicle, method for delivery, and primary site of
liver damage for each of the eight compounds are detailed in
Table 1. For each compound, control animal groups were
treated with vehicle alone. All animals were fasted for 12-18
hours prior to exposure. Groups of four to six animals were
dosed between 8:30 and 9:30 a.m.; thereafter, feed was pro-
vided ad libitum. After 6, 24 or 48 hours of treatment, ani-
mals were anesthetized by isoflurane anesthesia. Whole
blood was collected via retro-orbital plexus for hematology
Hierarchical clustering of animals in the high dose/48 hour group using SVM-derived classifiers Figure 2
Hierarchical clustering of animals in the high dose/48 hour group using SVM-derived classifiers. Two-way hierarchical clustering using Ward's minimum 
variance as the heuristic criteria and Euclidean distance as the similarity metric was performed on all of the animals in the high dose/48 hour group using 
the blood expression values for the 60 transcripts identified as compound classifiers for this dose/time group by a SVM algorithm. The degree of 
relatedness between each sample is represented by the dendrogram (hierarchical tree) presented in this figure, wherein the height of each branch 
represents the distance between the two objects being connected.http://genomebiology.com/2008/9/6/R100 Genome Biology 2008,     Volume 9, Issue 6, Article R100       Lobenhofer et al. R100.9
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and gene expression analysis. Serum was collected for clinical
chemistry. The animals were euthanized while under
anesthesia by cervical dislocation and necropsied within 4
minutes of sacrifice. The left liver lobe was promptly removed
and two defined cross sections were placed in 10% neutral
buffered formalin for subsequent histopathology. The
remainder of the left lobe was flash frozen for subsequent
RNA isolation based on established methods [40]. Experi-
ments were performed according to established guidelines
and an approved Animal Study Protocol was on file prior to
initiation of the study [41]. Additional data file 4 details the
date of death, method of sacrifice, initial and final body
weight along with gross findings/observations prior to and
during necropsy for every animal. These data are also availa-
ble in the Chemical Effects in Biological Systems (CEBS)
knowledgebase under the CEBS ID# 001-00001-0020-000-
4 [34].
Histopathology
The cross sections that were fixed by immersion in 10% neu-
tral buffered formalin (see 'In-life studies' section above)
were transferred to histology grade alcohol for 18-24 hours
after necropsy. Tissues were then processed, embedded in
paraffin, sectioned at 5 microns, and stained with hematoxy-
lin and eosin. A pathologist completed the initial microscopic
evaluation of each liver sample for a given compound. Grad-
ing criteria for each diagnosis are detailed in Additional data
file 5. An independent pathology quality assessment review
was performed by a second pathologist on the initial his-
topathological findings. A third pathologist reviewed the
quality assessment report and the slides and convened a con-
sistent group of four to five pathologists (including the two
mentioned above) to resolve any inconsistencies or discrep-
ancies in diagnoses and grading for all studies. Additional
data file 1 details the histopathological diagnoses and their
associated severity scores for each animal in the study. These
Hierarchical clustering of animals in the low dose/6 hour group using SVM-derived classifiers Figure 3
Hierarchical clustering of animals in the low dose/6 hour group using SVM-derived classifiers. Two-way hierarchical clustering using Ward's minimum 
variance as the heuristic criteria and Euclidean distance as the similarity metric was performed on all of the animals in the low dose/6 hour group using the 
blood expression values for the 160 transcripts identified as compound classifiers for this dose/time group by a SVM algorithm. The degree of relatedness 
between each sample is represented by the dendrogram (hierarchical tree) presented in this figure, wherein the height of each branch represents the 
distance between the two objects being connected.Genome Biology 2008, 9:R100
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data are also available in CEBS under the CEBS ID# 001-
00001-0020-000-4 [34].
Clinical chemistry
At sacrifice, blood was collected in clotting tubes (BD Micro-
tainer® Tubes, BD, Franklin Lakes, NJ, USA) and serum was
separated. Clinical chemistry analysis was performed on all
rats using a COBAS MIRA (Roche Diagnostics, Montclair, NJ,
USA) using commercially available reagents from Equal
Diagnostics (Exton, PA, USA) for the following assays: total
protein, albumin, cholesterol, creatinine, direct bilirubin,
total bilirubin, total bile acid, blood urea nitrogen and triglyc-
erides. In addition, an enzymatic activity for the following
proteins was measured: alanine aminotransferase, alkaline
phosphatase, aspartate aminotransferase, lactate dehydroge-
nase, and sorbitol dehydrogenase. Additional data file 1
details the clinical chemistry value for each of these parame-
ters for every animal. These data are also available in CEBS
under the CEBS ID# 001-00001-0020-000-4 [34].
PCA of transcripts identified as differentially expressed across the 'Response to hepatocellular injury' category in blood Figure 4
PCA of transcripts identified as differentially expressed across the 'Response to hepatocellular injury' category in blood. Blood expression data from the 30 
transcripts identified as differentially expressed across the Response to hepatocellular injury category from all 318 treated rats were subjected to PCA. 
The first principal component is represented by the x-axis, while the second principal component is represented by the y-axis. Each individual animal is 
represented as a circle and the relationship between the color of the circle and the categorical scores for the Response to hepatocellular injury is 
illustrated in the key.http://genomebiology.com/2008/9/6/R100 Genome Biology 2008,     Volume 9, Issue 6, Article R100       Lobenhofer et al. R100.11
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Hematology
Blood was collected in EDTA tubes (BD Microtainer® Tubes).
The samples were assayed using the Technicon H*1 hematol-
ogy analyzer (Bayer Corporation, Tarrytown, NY, USA). The
instrument performs white blood cell (WBC) counts by two
independent methods. The values must have agreed within
10%. Manual counts and smear estimates were used to con-
firm values, when necessary. To monitor red blood cell (RBC)
parameters, spun microhematocrits were performed for each
specimen for comparison with the automated hematocrit
(which is calculated from the directly measured RBCs and the
mean cell volume). Control products were assayed after every
tenth specimen. For WBC differential data, smears were
Wright-Giemsa stained using an Ames Hema-Tek II auto-
mated slide stainer (Bayer Corporation, Ames Division,
Elkhart, IN, USA) and manual WBC differential counts were
performed on the first sample in each group. For reticulocyte
counts, equal amounts of whole blood and New Methylene
Blue stain were allowed to incubate at room temperature for
at least 15 minutes. Smears were prepared and read to deter-
mine the percent reticulocytes per 1,000 RBCs. The percent
value is multiplied by the RBC count to determine the abso-
lute number of reticulocytes per microliter. Additional data
file 1 details the values for each of these parameters for every
animal. These data are also available in CEBS under the CEBS
ID# 001-00001-0020-000-4 [34].
RNA isolation and gene expression profiling
RNA was isolated from the flash frozen portion of the left lat-
eral liver lobe using RNeasy Midi columns (Qiagen, Valencia,
CA, USA) according to the manufacturer's protocol and also
from whole blood using the PaxGene Blood RNA Kit (Qia-
gen). The quantity and purity of the extracted RNA was eval-
uated using a NanoDrop ND-1000 spectrophotometer
(Nanodrop Technologies, Wilmington, DE, USA) and its
integrity measured using an Agilent Bioanalyzer. For micro-
array hybridizations performed on the Agilent platform, 1 μg
of total RNA from the left liver lobe or whole blood from
either an individual rat or a pooled sample representing time-
matched, vehicle control animals was amplified and labeled
with a fluorescent dye (either Cy3 or Cy5) using the Low RNA
Input Linear Amplification Labeling kit (Agilent Technolo-
gies, Palo Alto, CA, USA) following the manufacturer's proto-
col. The amount and quality of the fluorescently labeled cRNA
was assessed using a NanoDrop ND-1000 spectrophotometer
and an Agilent Bioanalyzer. Equal amounts of Cy3- or Cy5-
labeled cRNA were hybridized to the Agilent Rat Oligo Micro-
array (Agilent Technologies) for 17 hours, prior to washing
and scanning. Data were extracted from scanned images
using Agilent's Feature Extraction Software (Agilent Technol-
ogies). Fluorophore reversal hybridizations were performed
for 318 treated rats against time-matched control pools for
both tissue types (blood and liver) for a total of 1,272 hybrid-
izations. For microarray hybridizations performed on the
Affymetrix platform, 1 μg of total RNA from the left liver lobe
of each individual rat was labeled using the GeneChip One-
Cycle Target Labeling kit (Affymetrix, Inc., Santa Clara, CA,
USA) following the manufacturer's protocol. The amount and
quality of the cRNA was assessed using a NanoDrop ND-1000
spectrophotometer and an Agilent Bioanalyzer. The cRNA
was then fragmented and hybridized to the Rat Genome 230
2.0 Array (Affymetrix, Inc.) for 17 hours, prior to washing and
scanning. Data were extracted from scanned images using
GeneChip Operating Software (Affymetrix, Inc.). Hybridiza-
tions were performed on all treated and control animals for
each compound in addition to pooled control samples for two
of the compounds for a total of 432 hybridizations. These data
are also available in CEBS under the CEBS ID# 001-00001-
0020-000-4 [34].
Data analysis
Gene expression data were loaded into the Rosetta Resolver®
Gene Expression Analysis System version 6.0.0.0.311. Fluor-
ophore reversal hybridization data generated using the Agi-
lent platform were combined using an error-weighted
average for each individual animal. Data generated using the
Affymetrix platform were loaded using the Rosetta error
model for gene expression analysis [42]. Rosetta Resolver
was used to perform SVM-based analysis using a Gaussian
kernel function with three cross-validation loops, one-way
error-weighted ANOVA (with Bonferroni multiple test cor-
rection) and PCA. SVMs were used to identify compound-spe-
cific classifiers on each tissue type (blood and liver) within a
given dose/time group by randomly selecting two animals
from each compound within a given dose/time group to
which the SVM was performed to identify the classifiers.
Therefore, each SVM was performed on a total of 16 animals
(2 animals from each of the 8 compounds). A total of 18 SVMs
were performed. The Agilent ProbeIDs for each of the classi-
fiers that were identified in each of these SVMs are detailed in
Additional data file 2. Hierarchical clustering was also per-
formed in Rosetta Resolver using Ward's minimum variance
hierarchical clustering with Euclidean distance as the similar-
ity metric on ratios of gene expression data. GO enrichment
analysis was performed using High-Throughput GoMiner
[37,38].
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Additional data files
The following additional data are available with the online
version of this paper. Additional data file 1 is a table detailing
the histopathological scores as well as the clinical chemistry
and hematology data that were generated for each animal in
this project. Additional data file 2 is a table detailing the Agi-
lent probe identifiers that resulted from the SVM analyses
detailed in the Results section. Additional data file 3 is a table
detailing the enrichment p-values that resulted from per-
forming a GO enrichment analysis on the list of classifiers for
each dose/time/tissue group. GO categories must have had at
least five associated genes measured on the microarray in
order to be included. Additional data file 4 is a table detailing
all of the observations and measurements that were made
during the in-life portion of the project. Additional data file 5
is a table detailing the scoring method that was used for the
histopathological observations that were made in this project.
Additional data file 1 Histopathological scores and clinical chemistry and hematology  data Histopathological scores as well as the clinical chemistry and  hematology data that were generated for each animal in this  project. Click here for file Additional data file 2 Agilent probe identifiers Agilent probe identifiers that resulted from the SVM analyses  detailed in the Results section. Click here for file Additional data file 3 Enrichment p-values Enrichment p-values that resulted from performing a GO enrich- ment analysis on the list of classifiers for each dose/time/tissue  group. GO categories must have had at least five associated genes  measured on the microarray in order to be included. Click here for file Additional data file 4 Observations and measurements made during the in-life portion of  the project Observations and measurements made during the in-life portion of  the project. Click here for file Additional data file 5 Scoring method used for the histopathological observations made  in this project Scoring method used for the histopathological observations made  in this project. Click here for file
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